In its latest energy outlook, British energy giant BP predicts that fossil fuels as a primary energy source will decline from 80 percent in 2019 to between 55 and 20 percent in 2050, with renewables rising from 10 percent to between 35 and 65 percent. 

The forecast comes as BP adjusts its expectations around the green energy transition, due to the new uncertainties brought on by the war in Ukraine. 

"Global energy policies and discussions in recent years have been focused on the importance of decarbonizing the energy system and the transition to net zero," wrote BP Chief Economist Spencer Dale in a note. "The events of the past year have served as a reminder to us all that this transition also needs to take account of the security and affordability of energy."

As the report explained, energy security and affordability are competing with sustainability for countries' attention and investment dollars. BP calls this an "energy trilemma." 

"Any successful and enduring energy transition needs to address all three elements of the trilemma," Dale wrote. 

Yet the war in Ukraine isn't the only development changing BP's outlook. Another is the passing of the Inflation Reduction Act in the U.S., which is set to invest billions into green projects. 

The most positive scenarios, in terms of the climate, that BP outlines anticipate four trends:

In all possible cases, the report forecasts that renewables will be adopted  “quicker than any previous fuel in history."

Share:
More In Science
As U.S. Opioid Crisis Worsens, Price of Life-Saving Drug Naloxone Skyrockets
Jill Wagner and Baker Machado break down the state of the Opioid Crisis in the U.S. The CDC reported a 30% increase in overdose deaths from 2020 to 2021, but in recent months pharmaceutical companies have drastically raised the price of Naloxone or 'Narcan,' affecting the response of community harm prevention groups.
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Legal Questions Swirl as States Push Back Against Biden COVID Vaccine Mandate
The Biden Administration's mandate for COVID vaccinations by large employers has been put on hold by federal courts as GOP-led states and some businesses push back on the order's legality. Jonathan Adler, a law professor at Case Western Reserve University, joined Cheddar to discuss the legal challenges to implementing such mandates through OSHA (Occupational Safety and Health Administration). "Certainly expanding vaccinations is a good thing, and as vaccination rates go up that's better for all of us," Adler said. "But there are some legal questions about whether or not it's appropriate to use a law about occupational safety and health as the means to do that."
What COVID-19 Vaccines for Kids Might Mean for Fight Against Pandemic
Dr. Robert Frenck, an infectious disease specialist at Cincinnati Children's Hospital, joined Cheddar to talk about the significance of children ages 5-11 being authorized to receive COVID-19 vaccinations. He also discussed schools being cleared to administer vaccines and noted the importance of meeting people where they are rather than forcing them to find the shots. Frenck also said he expects that children under 5 years old will begin getting vaccinations sometime in spring.
Everything You Need to Know About Child Covid-19 Vaccines
A CDC advisory committee as unanimously voted to recommend the Pfizer Covid-19 vaccine in children ages 5 to 11. Dr. Amesh Adalja, Infectious Disease Specialist and Senior Scholar at Johns Hopkins Center for Health Security, joined Cheddar News to discuss.
Load More